INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...

MILFORD, Mass., PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to ...

Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca Results of Eisai Phase 2 pilot study supports the ...

GUILDFORD, UK / ACCESSWIRE / September 28, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has ...

- Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 - - Alixorexton ...

- Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, ...